Novel Epigenetic Reprogramming to Inhibit or Reverse EMT in Lung Cancer
Abstract
Carcinoma of the lung is the leading cause of cancer deaths in the US. The malignant properties of lung cancer, including invasion, metastasis and drug resistance, are driven inpart by the epithelial- mesenchymal transition (EMT), which makes this disease very difficult to treat. We hypothesized that TGF links NRP2-dependent signaling to upregulation of EZH2, an epigenetic modifier, and that EMT results from gene expression changes via a pathway of NRP2, ERK, ZEB1 and EZH2. We proposed to test the validity of this linkage, particularly the connection between NRP2, ZEB1 and EZH2, and to evaluate lung cancer susceptibilities to EZH2 inhibitors in combination with other epigenetic modifiers.
Document Details
- Document Type
- Technical Report
- Publication Date
- Sep 01, 2017
- Accession Number
- AD1048721
Entities
People
- Harry A. Drabkin
Organizations
- Medical University of South Carolina